T1	p 43 87	early-stage diabetic nephropathy patients on
T2	p 197 217	diabetic nephropathy
T3	p 320 352	Type 2 diabetic patients ( N.=57
T4	p 404 405	(
T5	p 450 492	Diabetic nephropathy patients were treated
T6	p 771 775	AGE-
T7	p 841 860	diabetic group with
T8	p 873 877	than
T9	p 970 983	group without
T10	p 1023 1028	group
T11	p 1046 1053	treated
T12	p 1061 1065	with
T13	p 1350 1405	type 2 diabetes mellitus patients with nephropathy than
T14	p 1438 1476	patients with nephropathy treated with
T15	i 97 121	and pyridoxine therapy .
T16	i 163 186	circulatory AGE-peptide
T17	i 248 301	thiamine ( vitamin B1 ) and pyridoxine ( vitamin B6 )
T18	i 505 507	B6
T19	i 524 541	mg/day ) or B1+B6
T20	i 757 766	phosphate
T21	i 1066 1071	B1+B6
T22	i 1489 1492	did
T23	o 6 39	Plasma AGE-peptides and C-peptide
T24	o 163 193	circulatory AGE-peptide levels
T25	o 653 756	glucose , HbA1c , triglyceride , cholesterol , insulin , C-peptide , thiamine pyrophosphate , pyridoxal
T26	o 809 821	AGE-peptides
T27	o 1196 1219	increase in C-peptide (
T28	o 1274 1304	measured , plasma AGE-peptides
T29	o 1529 1541	AGE-peptides
T30	o 1596 1604	increase
T31	o 1608 1619	C-peptide .